Featured Product
This Week in Quality Digest Live
FDA Compliance Features
Jill Roberts
Another way to know what’s too old to eat
Patricia Santos-Serrao
Four pharma quality trends
Del Williams
Preventing damage caused by large, suspended particles
Kari Miller
An effective strategy requires recruiting qualified personnel familiar with the process and technology

More Features

FDA Compliance News
Now is not the time to skip critical factory audits and supply chain assessments
Google Docs collaboration, more efficient management of quality deviations
Delivers time, cost, and efficiency savings while streamlining compliance activity
First trial module of learning tool focuses on ISO 9001 and is available now
Free education source for global medical device community
Good quality is adding an average of 11 percent to organizations’ revenue growth
Further enhances change management capabilities
Creates adaptive system for managing product development and post-market quality for devices with software elements
VQIP allows for expedited review and importation for approved applicants that demonstrate safe supply chains

More News

PharmaNet Development Group Inc.

FDA Compliance

PharmaNet Development Group Announces Observational Research Survey

Results to be released in November

Published: Monday, October 11, 2010 - 11:36

(PharmaNet Development Group: Princeton, NJ) -- PharmaNet Development Group Inc., a provider of drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, has released a new survey on pharmaceutical observational research, the fourth in an ongoing series. The survey is open to all in the industry with an interest in observational research and can be accessed here through Oct. 31.

“Pharmaceutical companies are increasingly looking to prospective observational research for compiling real-world data on post-approval clinical performance, economic value, patient quality of life, and product safety,” says Jeff Trotter, executive vice president, Phase IV Development, and creator of the survey. “While the scientific community excels at designing and executing controlled clinical trials, there may be less appreciation for the value of observational studies. The goal of the survey is to identify underlying issues in order to move toward more appropriately designed studies that improve the understanding of product performance among clients, regulators, policymakers, physicians, and patients.”

Previous surveys have revealed that drug-development organizations can benefit from broader cross functional collaboration and consensus on the strategy for observational research. The latest survey will continue to track evolving trends.

The results of this survey, plus the findings identified in previous surveys, are expected to be released in November. If you are interested in receiving the findings report or receiving more information on pharmaceutical observational research, contact aserody@pharmanet.com.


About The Author

PharmaNet Development Group Inc.’s picture

PharmaNet Development Group Inc.

PharmaNet Development Group Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. The company offers early- and late-stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III, and IV clinical development programs. With approximately 2,300 employees in 33 countries and more than 38 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development.